QC
REGN icon

Quadrature Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Quadrature Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6M Buy
49,073
+30,471
+164% +$20.7M 0.26% 85
2026
Q1 		$14.4M Sell
18,602
-9,009
-33% -$6.9M 0.17% 123
2025
Q4 		$21.3M Sell
27,611
-33,439
-55% -$22.7M 0.22% 100
2025
Q3 		$34.3M Sell
61,050
-9,399
-13% -$5.31M 0.41% 60
2025
Q2 		$37M Buy
+70,449
New +$39.3M 0.64% 37

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Quadrature Capital's REGN Position: Q2 2026 in Review

Quadrature Capital increased its Regeneron Pharmaceuticals (REGN) stake by 164% in Q2 2026, buying an estimated $20.7M and bringing the position to 49,073 shares worth $30.6M. The position accounts for 0.26% of the portfolio, ranked #85.

Quadrature Capital first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $37M in Q2 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Quadrature Capital held 49,073 shares of Regeneron Pharmaceuticals worth $30.6M as of Q2 2026.
  • Quadrature Capital bought 30,471 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $20.7M.
  • Regeneron Pharmaceuticals made up 0.26% of Quadrature Capital's portfolio in Q2 2026, its #85 holding.
  • Quadrature Capital first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Regeneron Pharmaceuticals position peaked at $37M in Q2 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.